| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_04c3dcc2e3046dc9ca3a8dbd5f5b41ce |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-351 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-117 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-59 |
| filingDate |
2019-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c9e00fec4044a7d99a0cec33b127866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcec7f347c8a636961df4e606e9f8066
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2c69640a6dc8ffd6586fec79c895344
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_193bea52c672da4f65f4635c28416784
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78e36454e6a3513dee171d5e06cdb733
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_162c7076c9c0d716dc79d80f571e8002 |
| publicationDate |
2019-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019262395-A1 |
| titleOfInvention |
Method of treating cancer |
| abstract |
A method of treating cancer can include administering a polyplex of a double stranded RNA and a polymeric conjugate. The polymeric conjugate can consist of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety can be conjugated via a linker to a targeting moiety capable of binding to a cancer antigen. |
| priorityDate |
2014-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |